Recent News

• 10.06.2025 - Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
• 09.25.2025 - Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
• 08.14.2025 - Leap Therapeutics Reports Second Quarter 2025 Financial Results
• 06.23.2025 - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
• 06.18.2025 - 2025 Annual Meeting
• 05.13.2025 - Leap Therapeutics Reports First Quarter 2025 Financial Results

Recent Filings

• 10.06.2025 - EX-99.1 EX-99.1
• 10.06.2025 - 8-K Current report
• 09.11.2025 - 8-K Current report
• 08.14.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities